Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Tenaya Therapeutics, Inc. Common Stock

TNYA

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

Last trade $0.3192
Day change -$0.0144 (-4.32%)
Day range $0.313 – $0.341
Volume 5,014,901
Market cap $76M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$75.22M
Price / earnings
—
Price / book
1.38×
Price / sales
24.81×
EV / sales
2.78×
EV / EBITDA
-0.11×

Profitability

Earnings per share
-$0.45
Return on assets
-132.73%
Return on equity
-186.69%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.78×
Quick ratio
3.78×
Cash ratio
3.55×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$54.65M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TNYA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.7M$1.11M$225K$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$1.7M$1.11M$225K$0$0$0$0$0
Selling, general and administrative$5.65M$5.41M$5.45M$5.98M$5.57M$6.71M$6.46M$5.96M
Research and development$14.87M$16.6M$14.84M$14.8M$15.36M$17.37M$21.08M$18.69M
Total operating expenses$21.18M$43.83M$20.29M$20.78M$20.94M$24.08M$27.54M$24.65M
Operating income-$19.48M-$42.72M-$20.07M-$20.78M-$20.94M-$24.08M-$27.54M-$24.65M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$18.94M-$43.39M-$19.27M-$20.18M-$20.28M-$23.28M-$26.86M-$23.84M
Income taxes$0$0$0$0$0$0$0$0
Net income-$18.94M-$43.39M-$19.27M-$20.18M-$20.28M-$23.28M-$26.86M-$23.84M
Net income attributable to common shareholders-$18.94M-$43.39M-$19.27M-$20.18M-$20.28M-$23.28M-$26.86M-$23.84M
EBITDA-$18.42M-$19.2M-$18.3M-$18.95M-$19.07M-$22M-$24.88M-$22.56M
Basic earnings per share-$0.08-$0.20-$0.09-$0.11-$0.12-$0.14-$0.24-$0.28
Diluted earnings per share-$0.08-$0.20-$0.09-$0.11-$0.12-$0.14-$0.24-$0.28

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Tenaya Therapeutics Stock Jumps After New Alnylam Deal

Tenaya Therapeutics shares surged 31.20% following a research collaboration agreement with Alnylam Pharmaceuticals focused on discovering genetic targets for cardiovascular disease treatments. Tenaya will validate up to 15 gene targets and receive up to $10 million in upfront payments with potential milestone payments reaching $1.13 billion. Despite the positive news, the stock remains in a bearish trend trading below its 100-day and 200-day moving averages.

GlobeNewswire Inc.

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies

The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.